Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + carboplatin + albumin-bound paclitaxel
- Development stage
- Phase 2
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This combination neoadjuvant regimen consists of tislelizumab, carboplatin, and albumin-bound paclitaxel (nab-paclitaxel). Tislelizumab is a humanized IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, blocking its interaction with PD-L1 and PD-L2 to restore T-cell mediated anti-tumor immune responses. Carboplatin is a platinum-based alkylating agent that induces DNA cross-linking, thereby inhibiting DNA synthesis and causing cell death. Albumin-bound paclitaxel is a microtubule inhibitor that stabilizes microtubules and prevents their disassembly, leading to cell cycle arrest and apoptosis. This specific chemo-immunotherapy doublet (TP) plus checkpoint inhibitor regimen is being investigated by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University as a neoadjuvant treatment for patients with early-stage oral squamous cell carcinoma (cT1-2N0M0) to enhance pathological response and improve event-free survival prior to surgical resection.
- Brand names
- Abraxane
- Other names
- tislelizumab + carboplatin + nab-paclitaxeltirellizumab + carboplatin + albumin-bound paclitaxeltislelizumab + TPtirellizumab + TP
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on tislelizumab + carboplatin + albumin-bound paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + carboplatin + albumin-bound paclitaxel.